Weekly Top News – IBD – September 7, 2020

llllllllll TD-1473 / J&JTD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study (clinicaltrials.gov) - Sep 3, 2020 - P2/3; N=500; Recruiting; Sponsor: Theravance Biopharma; Not yet recruiting --> Recruitingllllllllll Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Sep 2, 2020 - P3; N=931; Active, not recruiting; Sponsor: AbbVie; Recruiting --> Active, not recruitingllllllllll Remsima SC (infliximab biosimilar SC) / CelltrionCT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 3, 2020 - P3; N=615; Recruiting; Sponsor: Celltrion; Not yet recruiting --> Recruiting; Initiation date: Mar 2020 --> Sep 2020